Measuring CRN HLO 4 for 14/15 Delivering clinical research to

Slides:



Advertisements
Similar presentations
NHS R&D Jessica Bisset Acting Research Operations Manager UH Bristol.
Advertisements

AcoRD Implementation Amber O’Malley, CRN Funding and Contracts Manager & AcoRD Business Lead.
Copyright © 2012 Quintiles An Industry View of Working in NHS Wales Paula Jefferies – Site Relationship Manager Quintiles 11 th December 2012.
UH BRISTOL USING EDGE TO MONITOR OUR KPIs Jess Bisset
Delivering clinical research to make patients, and the NHS, better RESEARCH SITE INITIATIVE Aderonke Adebiyi dd/mm/yyyy.
National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP) A single system for processing and reviewing applications.
Supporting research to make patients, and the NHS, better Update on Clinical Research Network Performance - time for further improvement Dr Jonathan Sheffield.
1 Portfolio Simulation / Forecasting: Selecting improvement initiatives to maximize “points of leverage“ May 1, 2006 Alan Poirier Director, Analysis Metrics.
Delivering clinical research to make patients, and the NHS, better Haematological Cancer Research Report Site Specific Group Meeting Tuesday 14 th October.
Upper GI Research and Clinical Trials Update Bridget Workman Research Manager NECRN N 21 ST November 2012.
The Role of the Research Office Joint Research & Enterprise Office (JREO) St George’s University of London and St George’s University Hospitals NHS Foundation.
Delivering clinical research to make patients, and the NHS, better Finance in CRN: North Thames: Research Capability Funding, the receipt and distribution.
West Midlands (South) Comprehensive Local Research Network NIHR Governance Systems Regimantas Pestininkas Deputy Research Governance Manager 1 July 2010.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
Accessing the NHS for Research – NHS R&D Permissions Jemma Hughes R&D Manager ABMU Health Board.
Change to the Permissions process for Clinical Research Health Research Authority & UCLH Response UCL/UCLH Joint Research Office 2015/16.
Training for organisations participating in Peer Review of Paediatric Diabetes.
Update – April 2015 Champions for Research Support Meeting Delivering research to make patients, and the NHS, better.
Delivering clinical research to make patients, and the NHS, better Lymphs & Haems Cancer Research Report Site Specific Group Meeting Wednesday 16 th March.
Performance in Initiating and Delivering Clinical Research Why are we doing this? Through the NIHR (National Institute for Health Research) the Government.
Research and Development Dr Julie Hankin Medical Director.
Conference Series LLC Conferences Conference Series LLC is a pioneer and leading science event organizer, which publishes around 500 open access journals.
HRA Approval: training for non-commercial studies
Performance in Initiating and Delivering Clinical Research
London (South) Comprehensive Local Research Network
Eligibility Process for Cohort 4 & 5 HRA Approval Studies (post CSP) RM&G Lead’s 09 March 2015 Louise Lambert: Non-commercial Research Initiatives.
SWAG SSG Sarcoma Meeting
Royal Liverpool and Broadgreen Hospitals NHS Trust 2013/14 Plan
Patient and Public Involvement and Engagement in Research (PPIE)
Colorectal Cancer Research Report SWAG Site Specific Group
SWAG SSG Skin Cancer Meeting
RUNNING RANDOMISED CLINICAL TRIALS
SWAG SSG Colorectal Cancer Meeting
SWAG SSG Brain Meeting Wednesday 16th November 2016
SWAG SSG Sarcoma Meeting
Haematology/Lymphoma Research Report SWAG Site Specific Group
Performance in Initiating and Delivering Clinical Research
SWAG SSG Urology Cancer Meeting
SWAG SSG Upper GI Cancer Meeting
Scottish Government Health & Social Care Research Strategy
SWAG SSG Haematology and Lymphoma Meeting
SWAG SSG Sarcoma Cancer Meeting
The Role of the Oral Dental Specialty Group
SWAG SSG Brain and CNS Cancer Meeting
SWAG SSG Lung Cancer Meeting
The Development and Delivery of Research
Performance in Initiating and Delivering Clinical Research
SWAG SSG Gynaecological Cancers Meeting
SWAG SSG Head and Neck Cancer Meeting
SWAG SSG Sarcoma Meeting
Challenges of Recruitment in Haematology Trials
SWAG SSG Head and neck Cancer Meeting
Network support for researchers Jonathan Sheffield, Chief Executive
SWAG SSG Sarcoma Cancer Meeting
SWAG SSG Lung Cancer Meeting
UK-wide study: (lead R&D office in other UK nation) (Non-commercial)
Breast Cancer Research Report Site Specific Group Meeting Friday 10th July 2015 Dr Mark Beresford Network Sub Specialty Lead – Breast Cancer.
ACCORD UPDATE EVENTS 2019 Sponsorship and R&D
SWAG SSG Skin Cancer Meeting Wednesday 23rd May Research Report
SWAG SSG Haematology and Lymphoma Cancer Meeting
NIHR CRN High Level Objectives
Health Service R&D permissions
SWAG SSG Lung Cancer Meeting
SWAG SSG Skin Cancer Meeting
Safe Staffing Reports / NQB
SWAG SSG Brain Cancer Meeting
SWAG SSG Breast Cancer Meeting
SWAG SSG Upper GI Cancer Meeting
Lung Cancer Clinical Advisory Group
Urology Cancer Clinical Advisory Group
Presentation transcript:

Measuring CRN HLO 4 for 14/15 Delivering clinical research to make patients, and the NHS, better

The purpose of CRN HLO4 and the NIHR 70 day benchmark The purpose of CRN HLO 4 is to measure the time taken for a study to gain NHS permission at all associated sites. This is especially important to benchmark the UK globally for the life-sciences industry. The target is a median of 40 calendar days (from receipt of a valid complete application for the national study to NHS permission at all sites in a study). The purpose of the NIHR Performance in Initiating and Delivering Clinical Research exercise, relating to the 70-day benchmark, is to determine the time to achieve site NHS permission by the individual provider of NHS Services and achieve first patient recruited. The target is 70 days from valid research application at site)

The problem Currently CCRN asks Trusts to report against HLO 4 KPIs for NHS permission (30 days for study wide and 30 days for local review); some Trusts also report to CCF against the NIHR 70 day benchmark Performance of HLO4 has been split locally and reported on by Trust, which has caused confusion and tension when Trust Boards see conflicting data on site set up times. With the introduction of the LCRN structure, nearly all Trusts will have to report against the NIHR 70 day benchmark from 1st April because they will either hold Host contracts or step down agreements

The solution for 14/15 CRN HLO 4 will be adopted as an indicator of LCRN performance only for studies for which the LCRN is the lead Network (i.e. conducting study wide checks). LCRNs will not report and performance manage individual Trusts against HLO 4, as this is inappropriate and misleading. The targets for local and study wide checks will be amended to 15 days respectively but this will be a process target within CSP and detailed in the CRN Performance & Operating Framework (POF) and the CSP operating manual. This target will not be associated with HLO4. As the 70 day benchmark will come into effect for most Trusts from 1st April, the POF and the annual LCRN planning guidance states that Trusts will need to deliver against the 70 day benchmark for all clinical trials (portfolio and non-portfolio).

The solution for 14/15 continued The starting datapoint for CSP local checks will align the 70 day benchmark, and there will no longer be local clock stops from the 1st April. The responsibility for collecting, managing and acting upon data from the 70 day benchmark will remain with CCF